Skip to main content
Top
Published in: Acta Diabetologica 5/2017

01-05-2017 | Original Article

Serum 1,5-anhydroglucitol levels slightly increase rather than decrease after a glucose load in subjects with different glucose tolerance status

Authors: Hang Su, Xiaojing Ma, Jun Yin, Yufei Wang, Xingxing He, Yuqian Bao, Jian Zhou, Weiping Jia

Published in: Acta Diabetologica | Issue 5/2017

Login to get access

Abstract

Aims

Previous studies showed that serum 1,5-anhydroglucitol (1,5-AG) levels are significantly reduced in patients with diabetes mellitus (DM). However, it remains unclear how 1,5-AG levels acutely change in response to a glucose load. This study explored acute changes in 1,5-AG levels after a glucose load and the related influencing factors in individuals with differing degrees of glucose tolerance.

Methods

A total of 681 participants (353 without DM and 328 with DM) without a prior history of DM were enrolled. All participants underwent an oral glucose tolerance test. Fasting and postload (30, 60, 120, and 180 min) levels of plasma glucose, serum 1,5-AG, and insulin were measured.

Results

In all participant groups, serum 1,5-AG levels were slightly elevated after a glucose load and reached peak values at 120 min after loading (all P < 0.05). Regression analysis showed that body weight was negatively associated with the difference between peak and baseline 1,5-AG levels (Δ1,5-AG, standardized β = −0.119, P < 0.01). A strong and positive association between 1,5-AG0 and Δ1,5-AG was also found independent of other confounding factors (standardized β = 0.376, P < 0.01). The ratio of the Δ1,5-AG to the 1,5-AG0 was higher in DM patients (7.3% [3.4–11.5%]) than in those without DM (6.2% [3.6–9.2%]).

Conclusions

In contrast to the established decline in 1,5-AG levels with long-term hyperglycemia, the present study showed that serum 1,5-AG levels slightly increased by 6–7% after a glucose load. Further studies in different 1,5-AG transport models are needed to investigate the relevant metabolic pathways.
Literature
1.
2.
go back to reference Ma X, Hao Y, Hu X et al (2015) 1,5-anhydroglucitol is associated with early-phase insulin secretion in chinese patients with newly diagnosed type 2 diabetes mellitus. Diabetes Technol Ther 17(5):320–326CrossRefPubMed Ma X, Hao Y, Hu X et al (2015) 1,5-anhydroglucitol is associated with early-phase insulin secretion in chinese patients with newly diagnosed type 2 diabetes mellitus. Diabetes Technol Ther 17(5):320–326CrossRefPubMed
3.
go back to reference McGill JB, Cole TG, Nowatzke W et al (2004) Circulating 1,5-anhydroglucitol levels in adult patients with diabetes reflect longitudinal changes of glycemia: a U.S. trial of the GlycoMark assay. Diabetes Care 27(8):1859–1865CrossRefPubMed McGill JB, Cole TG, Nowatzke W et al (2004) Circulating 1,5-anhydroglucitol levels in adult patients with diabetes reflect longitudinal changes of glycemia: a U.S. trial of the GlycoMark assay. Diabetes Care 27(8):1859–1865CrossRefPubMed
4.
go back to reference Nerby CL, Stickle DF (2009) 1,5-anhydroglucitol monitoring in diabetes: a mass balance perspective. Clin Biochem 42(3):158–167CrossRefPubMed Nerby CL, Stickle DF (2009) 1,5-anhydroglucitol monitoring in diabetes: a mass balance perspective. Clin Biochem 42(3):158–167CrossRefPubMed
5.
go back to reference Stettler C, Stahl M, Allemann S et al (2008) Association of 1,5-anhydroglucitol and 2-h postprandial blood glucose in type 2 diabetic patients. Diabetes Care 31(8):1534–1535CrossRefPubMedPubMedCentral Stettler C, Stahl M, Allemann S et al (2008) Association of 1,5-anhydroglucitol and 2-h postprandial blood glucose in type 2 diabetic patients. Diabetes Care 31(8):1534–1535CrossRefPubMedPubMedCentral
6.
go back to reference Dungan KM, Buse JB, Largay J et al (2006) 1,5-anhydroglucitol and postprandial hyperglycemia as measured by continuous glucose monitoring system in moderately controlled patients with diabetes. Diabetes Care 29(6):1214–1219CrossRefPubMed Dungan KM, Buse JB, Largay J et al (2006) 1,5-anhydroglucitol and postprandial hyperglycemia as measured by continuous glucose monitoring system in moderately controlled patients with diabetes. Diabetes Care 29(6):1214–1219CrossRefPubMed
7.
go back to reference Kim MJ, Jung HS, Hwang-Bo Y et al (2013) Evaluation of 1,5-anhydroglucitol as a marker for glycemic variability in patients with type 2 diabetes mellitus. Acta Diabetol 50(4):505–510CrossRefPubMed Kim MJ, Jung HS, Hwang-Bo Y et al (2013) Evaluation of 1,5-anhydroglucitol as a marker for glycemic variability in patients with type 2 diabetes mellitus. Acta Diabetol 50(4):505–510CrossRefPubMed
9.
go back to reference Yamanouchi T, Shinohara T, Ogata N, Tachibana Y, Akaoka I, Miyashita H (1996) Common reabsorption system of 1,5-anhydro-d-glucitol, fructose, and mannose in rat renal tubule. Biochim Biophys Acta 1291(1):89–95CrossRefPubMed Yamanouchi T, Shinohara T, Ogata N, Tachibana Y, Akaoka I, Miyashita H (1996) Common reabsorption system of 1,5-anhydro-d-glucitol, fructose, and mannose in rat renal tubule. Biochim Biophys Acta 1291(1):89–95CrossRefPubMed
10.
go back to reference Akanuma Y, Morita M, Fukuzawa N, Yamanouchi T, Akanuma H (1988) Urinary excretion of 1,5-anhydro-d-glucitol accompanying glucose excretion in diabetic patients. Diabetologia 31(11):831–835CrossRefPubMed Akanuma Y, Morita M, Fukuzawa N, Yamanouchi T, Akanuma H (1988) Urinary excretion of 1,5-anhydro-d-glucitol accompanying glucose excretion in diabetic patients. Diabetologia 31(11):831–835CrossRefPubMed
11.
go back to reference Goto M, Yamamoto-Honda R, Shimbo T et al (2011) Correlation between baseline serum 1,5-anhydroglucitol levels and 2-h post-challenge glucose levels during oral glucose tolerance tests. Endocr J 58(1):13–17CrossRefPubMed Goto M, Yamamoto-Honda R, Shimbo T et al (2011) Correlation between baseline serum 1,5-anhydroglucitol levels and 2-h post-challenge glucose levels during oral glucose tolerance tests. Endocr J 58(1):13–17CrossRefPubMed
12.
go back to reference Department of Noncommunicable Disease Surveillance (1999) Report of a WHO Consultation: definition, diagnosis and classification of diabetes mellitus and its complication: Part1: diagnosis and classification of diabetes mellitus. World Health Organization, Geneva Department of Noncommunicable Disease Surveillance (1999) Report of a WHO Consultation: definition, diagnosis and classification of diabetes mellitus and its complication: Part1: diagnosis and classification of diabetes mellitus. World Health Organization, Geneva
13.
go back to reference World Health Organization (2000) Obesity: preventing and managing the global epidemic. Report of a WHO consultation. World Health Organ Tech Rep Ser 894:1–253 World Health Organization (2000) Obesity: preventing and managing the global epidemic. Report of a WHO consultation. World Health Organ Tech Rep Ser 894:1–253
14.
go back to reference Nowak N, Skupien J, Cyganek K, Matejko B, Malecki MT (2013) 1,5-Anhydroglucitol as a marker of maternal glycaemic control and predictor of neonatal birthweight in pregnancies complicated by type 1 diabetes mellitus. Diabetologia 56(4):709–713CrossRefPubMedPubMedCentral Nowak N, Skupien J, Cyganek K, Matejko B, Malecki MT (2013) 1,5-Anhydroglucitol as a marker of maternal glycaemic control and predictor of neonatal birthweight in pregnancies complicated by type 1 diabetes mellitus. Diabetologia 56(4):709–713CrossRefPubMedPubMedCentral
15.
go back to reference Wang Y, Yuan Y, Zhang Y et al (2016) Serum 1,5-anhydroglucitol level as a screening tool for diabetes mellitus in a community-based population at high risk of diabetes. Acta Diabetol Nov 28 [Epub ahead of print] Wang Y, Yuan Y, Zhang Y et al (2016) Serum 1,5-anhydroglucitol level as a screening tool for diabetes mellitus in a community-based population at high risk of diabetes. Acta Diabetol Nov 28 [Epub ahead of print]
16.
go back to reference Sun J, Dou JT, Wang XL et al (2011) Correlation between 1,5-anhydroglucitol and glycemic excursions in type 2 diabetic patients. Chin Med J (Engl) 124(22):3641–3645 Sun J, Dou JT, Wang XL et al (2011) Correlation between 1,5-anhydroglucitol and glycemic excursions in type 2 diabetic patients. Chin Med J (Engl) 124(22):3641–3645
17.
go back to reference Pramodkumar TA, Jayashri R, Gokulakrishnan K et al (2016) Relationship of glycemic control markers—1,5 anhydroglucitol, fructosamine, and glycated hemoglobin among Asian Indians with different degrees of glucose intolerance. Indian J Endocrinol Metab 20(5):690–695CrossRefPubMedPubMedCentral Pramodkumar TA, Jayashri R, Gokulakrishnan K et al (2016) Relationship of glycemic control markers—1,5 anhydroglucitol, fructosamine, and glycated hemoglobin among Asian Indians with different degrees of glucose intolerance. Indian J Endocrinol Metab 20(5):690–695CrossRefPubMedPubMedCentral
18.
go back to reference Ma X, Hu X, Zhou J et al (2015) Glycated albumin is more closely correlated with coronary artery disease than 1,5-anhydroglucitol and glycated hemoglobin A1c. Cardiovasc Diabetol 14:16CrossRefPubMedPubMedCentral Ma X, Hu X, Zhou J et al (2015) Glycated albumin is more closely correlated with coronary artery disease than 1,5-anhydroglucitol and glycated hemoglobin A1c. Cardiovasc Diabetol 14:16CrossRefPubMedPubMedCentral
19.
go back to reference Selvin E, Rawlings A, Lutsey P et al (2016) Association of 1,5-Anhydroglucitol with cardiovascular disease and mortality. Diabetes 65(1):201–208PubMed Selvin E, Rawlings A, Lutsey P et al (2016) Association of 1,5-Anhydroglucitol with cardiovascular disease and mortality. Diabetes 65(1):201–208PubMed
20.
go back to reference Kim WJ, Park CY, Park SE et al (2012) Serum 1,5-anhydroglucitol is associated with diabetic retinopathy in Type 2 diabetes. Diabet Med 29(9):1184–1190CrossRefPubMed Kim WJ, Park CY, Park SE et al (2012) Serum 1,5-anhydroglucitol is associated with diabetic retinopathy in Type 2 diabetes. Diabet Med 29(9):1184–1190CrossRefPubMed
21.
go back to reference Watanabe M, Kokubo Y, Higashiyama A, Ono Y, Miyamoto Y, Okamura T (2011) Serum 1,5-anhydro-d-glucitol levels predict first-ever cardiovascular disease: an 11-year population-based cohort study in Japan, the Suita study. Atherosclerosis 216(2):477–483CrossRefPubMed Watanabe M, Kokubo Y, Higashiyama A, Ono Y, Miyamoto Y, Okamura T (2011) Serum 1,5-anhydro-d-glucitol levels predict first-ever cardiovascular disease: an 11-year population-based cohort study in Japan, the Suita study. Atherosclerosis 216(2):477–483CrossRefPubMed
22.
go back to reference Ikeda N, Hara H, Hiroi Y (2015) Ability of 1,5-anhydro-d-glucitol values to predict coronary artery disease in a non-diabetic population. Int Heart J 56(6):587–591CrossRefPubMed Ikeda N, Hara H, Hiroi Y (2015) Ability of 1,5-anhydro-d-glucitol values to predict coronary artery disease in a non-diabetic population. Int Heart J 56(6):587–591CrossRefPubMed
23.
go back to reference Ikeda N, Hara H, Hiroi Y (2014) 1,5-Anhydro-d-glucitol predicts coronary artery disease prevalence and complexity. J Cardiol 64(4):297–301CrossRefPubMed Ikeda N, Hara H, Hiroi Y (2014) 1,5-Anhydro-d-glucitol predicts coronary artery disease prevalence and complexity. J Cardiol 64(4):297–301CrossRefPubMed
24.
go back to reference Fujiwara T, Yoshida M, Yamada H et al (2015) Lower 1,5-anhydroglucitol is associated with denovo coronary artery disease in patients at high cardiovascular risk. Heart Vessels 30(4):469–476CrossRefPubMed Fujiwara T, Yoshida M, Yamada H et al (2015) Lower 1,5-anhydroglucitol is associated with denovo coronary artery disease in patients at high cardiovascular risk. Heart Vessels 30(4):469–476CrossRefPubMed
25.
go back to reference Takahashi S, Shimada K, Miyauchi K et al (2016) Low and exacerbated levels of 1,5-anhydroglucitol are associated with cardiovascular events in patients after first-time elective percutaneous coronary intervention. Cardiovasc Diabetol 15(1):145CrossRefPubMedPubMedCentral Takahashi S, Shimada K, Miyauchi K et al (2016) Low and exacerbated levels of 1,5-anhydroglucitol are associated with cardiovascular events in patients after first-time elective percutaneous coronary intervention. Cardiovasc Diabetol 15(1):145CrossRefPubMedPubMedCentral
26.
go back to reference Kato A, Kunimatsu T, Yamashita Y, Adachi I, Takeshita K, Ishikawa F (2013) Protective effects of dietary 1,5-anhydro-d-glucitol as a blood glucose regulator in diabetes and metabolic syndrome. J Agric Food Chem 61(3):611–617CrossRefPubMed Kato A, Kunimatsu T, Yamashita Y, Adachi I, Takeshita K, Ishikawa F (2013) Protective effects of dietary 1,5-anhydro-d-glucitol as a blood glucose regulator in diabetes and metabolic syndrome. J Agric Food Chem 61(3):611–617CrossRefPubMed
27.
go back to reference Yamanouchi T, Inoue T, Ichiyanagi K, Sakai T, Ogata N (2003) 1,5-Anhydroglucitol stimulates insulin release in insulinoma cell lines. Biochim Biophys Acta 1623(2–3):82–87CrossRefPubMed Yamanouchi T, Inoue T, Ichiyanagi K, Sakai T, Ogata N (2003) 1,5-Anhydroglucitol stimulates insulin release in insulinoma cell lines. Biochim Biophys Acta 1623(2–3):82–87CrossRefPubMed
28.
go back to reference Stickle D, Turk J (1997) A kinetic mass balance model for 1,5-anhydroglucitol: applications to monitoring of glycemic control. Am J Physiol 273(4 Pt 1):E821–E830PubMed Stickle D, Turk J (1997) A kinetic mass balance model for 1,5-anhydroglucitol: applications to monitoring of glycemic control. Am J Physiol 273(4 Pt 1):E821–E830PubMed
29.
go back to reference Yamanouchi T, Akaoka I, Akanuma Y, Akanuma H, Miyashita E (1990) Mechanism for acute reduction of 1,5-anhydroglucitol in rats treated with diabetogenic agents. Am J Physiol 258(3 Pt 1):E423–E427PubMed Yamanouchi T, Akaoka I, Akanuma Y, Akanuma H, Miyashita E (1990) Mechanism for acute reduction of 1,5-anhydroglucitol in rats treated with diabetogenic agents. Am J Physiol 258(3 Pt 1):E423–E427PubMed
30.
go back to reference Yamanouchi T, Akanuma H, Takaku F, Akanuma Y (1986) Marked depletion of plasma 1,5-anhydroglucitol, a major polyol, in streptozocin-induced diabetes in rats and the effect of insulin treatment. Diabetes 35(2):204–209CrossRefPubMed Yamanouchi T, Akanuma H, Takaku F, Akanuma Y (1986) Marked depletion of plasma 1,5-anhydroglucitol, a major polyol, in streptozocin-induced diabetes in rats and the effect of insulin treatment. Diabetes 35(2):204–209CrossRefPubMed
Metadata
Title
Serum 1,5-anhydroglucitol levels slightly increase rather than decrease after a glucose load in subjects with different glucose tolerance status
Authors
Hang Su
Xiaojing Ma
Jun Yin
Yufei Wang
Xingxing He
Yuqian Bao
Jian Zhou
Weiping Jia
Publication date
01-05-2017
Publisher
Springer Milan
Published in
Acta Diabetologica / Issue 5/2017
Print ISSN: 0940-5429
Electronic ISSN: 1432-5233
DOI
https://doi.org/10.1007/s00592-017-0968-z

Other articles of this Issue 5/2017

Acta Diabetologica 5/2017 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.